Welcome to our dedicated page for Nanoviricides SEC filings (Ticker: NNVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NanoViricides, Inc. filings document the formal disclosures of a clinical-stage antiviral drug developer listed on NYSE American under the symbol NNVC. The company’s SEC record covers material events, proxy governance, stockholder voting matters and capital-raising transactions tied to its common stock and other securities.
Recent filings include Form 8-K reports on annual-meeting voting results, a registered direct offering involving common stock and pre-funded warrants, and officer compensation arrangements. Proxy materials describe board elections, advisory compensation votes, auditor ratification and related governance procedures. The filings also identify capital-structure elements such as common stock, Series A convertible preferred stock and shelf-registration-based financing activity.
NanoViricides, Inc. (NNVC) reported the results of its 2025 Annual Meeting of Stockholders. A quorum was present, with 7,906,820 common shares and 838,025 Series A Convertible Preferred shares entitled to vote, representing approximately 61% of the company’s outstanding voting capital stock.
Stockholders re-elected Anil Diwan as a Class I Director, with 9,757,652 votes for, 173,096 against, and 48,971 abstentions. An advisory vote on the compensation of the named executive officers also passed, receiving 9,500,223 votes for, 420,374 against, and 59,122 abstentions. Stockholders further ratified the appointment of EisnerAmper, LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 14,594,257 votes for, 194,416 against, and 60,051 abstentions.
NanoViricides, Inc. announced a capital raise combining a registered direct offering and a concurrent private placement. The company sold 1,970,000 registered shares at $1.68 and issued pre-funded warrants for 1,601,429 shares at $1.67999 with a $0.00001 exercise price, immediately exercisable. In the private placement, it issued Series A and Series B warrants for up to 3,571,429 shares each, exercisable six months after issuance at $1.75 (A, two-year term) and $2.00 (B, five-and-a-half-year term).
The transaction closed on November 12, 2025, generating approximately $6.0 million in gross proceeds before fees, to be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as placement agent for a 7.0% cash fee, plus up to $60,000 in expenses and $15,000 in non-accountable expenses. The company agreed to a 90-day restriction on new equity issuances and filings, a 180-day prohibition on variable rate transactions, and 90-day lock-ups by directors and officers.
NanoViricides, Inc. filed its quarterly results for the period ended September 30, 2025, reporting a net loss of $1.79 million, improved from $3.13 million a year ago, as operating expenses fell to $1.80 million. Cash and cash equivalents were $1.13 million, with total assets of $8.36 million and current liabilities of $1.18 million.
Management stated that, despite raising $1.25 million via at‑the‑market sales during the quarter, and approximately $6 million in a registered direct offering completed on November 12, 2025 (plus additional ATM proceeds), there is substantial doubt about the Company’s ability to continue as a going concern. The Company also has access to a $3 million related‑party line of credit, undrawn at quarter‑end. Shares outstanding were 17,556,079 as of September 30, 2025; approximately 17,997,000 were outstanding as of November 14, 2025.
Operationally, the company highlighted progress for lead antiviral NV‑387, including completion of a Phase I safety trial and a final approval from DRC’s ACOREP in late October 2025 to start a Phase II MPox study, subject to conditions.
NanoViricides, Inc. launched a registered direct offering of 1,970,000 shares of common stock at $1.68 per share and pre-funded warrants to purchase up to 1,601,429 shares at $1.67999 per pre-funded warrant. This filing also covers 1,601,429 shares issuable upon exercise of those pre-funded warrants at an exercise price of $0.00001 per share, which are immediately exercisable.
The offering size is $6,000,000 in gross proceeds, with a 7% placement fee of $420,000; the company expects approximately $5,505,000 in net proceeds, earmarked for general corporate purposes including working capital, R&D and clinical trial expenditures. A.G.P./Alliance Global Partners is acting as exclusive placement agent on a reasonable best efforts basis.
In a concurrent private placement, the company is selling Series A warrants to purchase up to 3,571,429 shares at $1.75 (exercisable beginning six months for 18 months) and Series B warrants to purchase up to 3,571,429 shares at $2.00 (exercisable beginning six months for five years); these PIPE securities are not registered here. Shares outstanding were 18,006,532 immediately after the offering, as of November 10, 2025.
NanoViricides, Inc. filed Amendment No. 2 to its prospectus supplement for its at-the-market offering, updating the maximum amount available to sell to $0 under its Form S-3 program with D. Boral Capital LLC (formerly EF Hutton) as agent.
The company states it may not currently offer and sell common stock through or to the agent pursuant to the prospectus as amended. This update reflects the Form S-3 General Instruction I.B.6 limitations tied to public float. As of November 10, 2025, public float was $34,719,086, based on 17,359,543 non‑affiliate shares at $2.00 per share. Over the prior 12 months, the company has offered and sold approximately $5,009,140 of common stock under I.B.6.
The company notes that if its public float changes, it may sell up to one‑third of its public float on Form S‑3, subject to the Sales Agreement, and that the I.B.6 cap no longer applies if public float exceeds $75 million.
NanoViricides, Inc. is presenting a definitive proxy for a shareholder meeting that includes the election of one Class I director and discusses director and executive compensation principles. The election requires a plurality vote with only "For" or "Withheld" votes counting and broker non-votes having no effect. The document emphasizes tying executive pay to company performance through annual bonuses and long-term awards that consider financial and individual goals and corporate values. It also discloses non-employee director equity holdings: Dr. Jawadekar 41,536, Mr. Rokita 41,009, and Mr. Zucker 39,786.
NanoViricides, Inc. filed an 8-K disclosing several exhibit-level agreements that were furnished with the report. The filing lists extensions of employment agreements for Anil Diwan and Meeta Vyas, with Meeta Vyas’s extension effective July 1, 2025. It also furnishes credit-and-collateral documents dated September 23, 2025: an amendment to a line of credit, an open-ended promissory note, and an open-ended mortgage deed. The report is signed by Anil Diwan as President and Chairman and dated October 1, 2025.
The filing provides the existence and dates of these agreements but contains no financial tables, amounts, or detailed terms in the provided text. The exhibits indicate personnel continuity at the executive level and new or amended financing arrangements secured on September 23, 2025, but the document fragment does not disclose monetary values, interest rates, collateral descriptions, covenants, or counterparty names beyond what is listed.
NanoViricides, Inc. (NNVC) is a development-stage biopharmaceutical company focused on nanoviricide antiviral drug candidates and has no commercial products or revenue. The filing discloses a net loss of approximately $9.5 million and net cash used in operating activities of about $8.5 million for the year, cash and cash equivalents of approximately $1.6 million at June 30, 2025, and additional ATM equity sales of about $1.25 million through September 24, 2025. Management states substantial doubt about the company’s ability to continue as a going concern absent additional financing and available credit under a $3.0 million line of credit. The company reports ongoing preclinical and clinical activities for NV-387 (multiple Indications including MPox, ARI/SARI, RSV and COVID formulations), license arrangements with milestone and royalty obligations, and reliance on third-party collaborators for trials, manufacturing and commercialization.